Compound Screening TRIZ Cases

This case uses API5-targeting antibodies to increase apoptosis and inhibit tumors resistant to conventional anticancer drugs.

This case uses hSATII RNA suppression or increased CTCF expression to selectively eliminate senescent cells and detect disease early.

This case uses Cf48 in blood or tissue to assess kidney injury, predict prognosis, and guide anti-fibrosis treatment.

This case uses antibodies from vaccinated patients to identify shared antigens for a standardized tumor vaccine.

A compound inhibits STAT3 Ser727 phosphorylation to improve insulin sensitivity.

A peptide molecule blocks Src family kinase interaction with androgen or estradiol receptors to inhibit non-genomic signaling pathways.

Transgenic mice expressing human IL-17A resolve antibody recognition gaps in autoimmune disease research.

Novel bifunctional molecules facilitate targeted protein degradation via proteasomal pathways, overcoming resistance in low E3 ligase cells.

Engineered biomaterial scaffolds stabilize human parenchymal cells to support rapid in vivo engraftment.

A Triplex-Forming Tag enables specific protein isolation via stable triple helix formation with oligonucleotide probes.

Truncated beta-galactosidase donor fragments complex with acceptor segments to produce robust enzymatic signals while minimizing background interference.

A recombinant membrane span protein complex fuses a constitutive kinase to detect ligand-receptor binding events.

A CRISPR-Cas9 and transposon vector system modifies liver cells to generate recurrent hepatocellular carcinoma models in immune-competent mice.

A peptide binds the p68 IQ motif to block calmodulin interaction and stop cancer cell migration.

Agents block EWS-FLI1 recruitment of BAF complexes to reduce cancer cell viability.

Stabilized ubiquitin proteins enhance binding affinity to deubiquitinases through targeted amino acid substitutions.

Immunomodulatory compounds treat refractory cancers by inhibiting TNF-alpha production while enhancing T-cell proliferation to reduce toxicity.

Antibody mimetics target the unique allosteric PIF pocket of Aurora A kinase, avoiding conserved ATP sites to eliminate side effects from non-specific binding.

Downstream molecular markers proxy UBE3A activity, resolving measurement difficulties while enabling precise therapeutic monitoring.

Reductive alkylation of aromatic amines incorporates diverse chemical groups into polypeptides, resolving low incorporation efficiency.

NME proteins revert cancer cells to a naïve state, enabling reliable drug efficacy testing by resolving low engraftment rates in mouse models.

A close contact surface density method calculates residue packing by dividing close contact potentials by exposed contact area.

Segmented peptide coatings on stents inhibit neointimal formation by blocking smooth muscle cell proliferation while preserving endothelial cell survival.

Fc-gamma receptor mutants extend serum half-life of protein drugs by optimizing amino acid sequences to improve IgG binding affinity.

A recombinant cell assay uses ubiquitin proteasome degradation to measure botulinum neurotoxin activity via label disappearance.

A method scans molecular diversity using iterative library design with carbohydrate scaffolds to identify active compounds.

A method screens compounds that interact with Cap-Binding Proteins CBP20 and CBP80 to inhibit viral replication.

Proteomic markers resolve genetic material instability by detecting stable proteins, enabling early hepatocellular carcinoma diagnosis.

Fusing human and mouse T1R2 and T1R3 domains creates chimeric receptors that resolve low sensitivity in distinguishing activators from regulators.

Segmented biochemical assays using purified proteins resolve the contradiction between inhibitor selectivity and assay complexity.

Calcitonin receptor binding detects cell death in live cells without special buffers or membrane harvesting.

A nucleic acid reporter gene enables specific detection of infected cells through site-specific recombination.

Extracting SAB from mitochondrial fractions isolates the biomarker, resolving prediction accuracy issues caused by general immune response factors.

Modified peptides with D-amino acid substitutions act as sustained antagonists against substance P and hemokinin-1 receptors.

A screening method detects orexigenic potential of psychotropic drugs by measuring hypothalamic AMPK phosphorylation levels.